Suppliers
Contact Us
GENTAUR Europe BVBA Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45 Fax 0032 16 50 90 45 This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. |
GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GmbH Marienbongard 20
52062 Aachen Deutschland
Tel (+49) 0241 56 00 99 68
Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531
Fax 020 8445 9411
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893
Fax 0497-517897
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Spain
Tel 0911876558
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Phone/Fax:
(408) 780-0908
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENPRICE Inc. invoicing/ accounting:
6017 Snell Ave, Suite 357
San Jose, CA. 96123
Serbia, Macedonia,
Montenegro, Croatia:
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Romania
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Greece
Tel 00302111768494
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
Other countries
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Ceská republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Magyarország Budapest +3619980547
Scientists analyze the DNA of Flatworms
For the first time scientists have deciphered the DNA of flat worms, which may reveal new therapeutic targets for future drugs. The genome is a new resource and the path to faster development of new drugs are urgently needed - flat worms cause two of the seventeen "neglected" tropical diseases listed by the World Health Organization - echinococcosis and cysticercosis.
The research team determined the DNA sequence of the four types of tapeworms to better study the biology and genetics of intestinal parasites. In most species, adults cause few complaints while in the intestines. The larvae, however, can cause serious medical complications in moving their body. They form cysts in the bodies of humans and animals, which can lead to complications such as blindness or epilepsy.
According to Dr. Matthew Beriman of the Wellcome Trust Sanger Institute, parasitosis of flat worms are widespread. Their global burden is comparable to that of multiple sclerosis and melanoma.
Typically, the researchers analyzed the DNA of pathogens and compare it with that of man, and thus identify potential targets for future drugs. In this study, however, researchers are mainly interested in the similarities in the DNA of human intestinal parasites. This is because unlike most pathogens such as bacteria and viruses, flat worms are eukaryotic organisms like humans. Flatworms much more like a human structure and physiology of any bacteria or virus.
Furthermore, by analyzing the similarities between the genomes, researchers discovered which of already existing drugs might be effective against parasites. This can save hundreds of decades of work and millions of dollars in investments.
It turns out that some tapeworms are sensitive to the drugs currently used to treat cancer. Another potential solution is cholesterol lowering medication. In the course of evolution, flat worms have lost the ability to synthesize their own cholesterol, which obtain at the expense of the host. Promising target for new drugs are proteins, through which the larvae absorb cholesterol from the intestine. If the function of these proteins has been crossed, the larvae will stop development and will die.
Invented a pill to quickly sober
Studies of "drug" are still in a very early stage and tests are performed only on mice.
Soon fans will be able to cup sober just one pill. Researchers made a cocktail of alcohol metabolizing enzymes rapidly reduce the level of alcohol in the blood while drunk mouse forward "Daily Mail".
"Treatment", which compares with having millions of liver cells in your stomach, you may have a lasting impact on fans of spirits. Yangfeng Lou - professor of chemistry and biomolecular engineering, and Cheng Zhi - Professor of Biochemistry and Molecular Biology at the University of Southern California, injected mice with drunk nanocapsule containing two enzymes. One of the enzymes - oxidase comes as a by-product of hydrogen peroxide, which can be harmful. That's why he has to work with another enzyme to break down hydrogen peroxide. The study shows that drunken mice that were injected with these nanocapsule, sobered much faster than those who did not receive enzyme "treatment". The breakthrough is still in a very early stage and can not speak for its application in humans.
But expert Lou argues that experience can lead to the invention of a new drug to act as an antidote to alcohol. He states that "drug" can be taken as a simple pill. "It's like you have millions of liver cells in your stomach that help you revise alcohol," said Professor Lu.
Trastuzumab increases the relative risk of brain metastases
According to a report published in the Annals of Oncology, women with Herr-2 positive breast cancer who received trastuzumab as adjuvant therapy are at significantly increased risk of metastases in the central nervous system as a first recurrence of the tumor.
According to Dr. Erin Olson, a neurologist at Ohio State University and author of the study, trastuzumab significantly reduced the risk of recurrence, but clinicians should be aware that it increases the risk of them occur in the nervous system. Physicians should carefully monitor patients for neurologic symptoms.
It is suggested that the nervous system is the "refuge" for micro metastatic tumors because trastuzumab does not cross the blood-brain barrier or because tumor cells that do not overexpress Herr-2 receptor migrate more easily into the brain.
In previous studies, Dr. Olson and her team showed that anti Herr-2 targeted therapies increase the frequency of brain metastases. This spurred her to investigate the relationship between brain metastases and trastuzumab. The team analyzed four Phase III clinical trials with a total of 9,020 participants.
Since 4921 women receiving trastuzumab, 125 relapse in the breast (incidence of 2.56%). Of 4099 women who received trastuzumab, 78 relapse of the tumor in the brain (1.94%). In patients treated with trastuzumab treatment brain metastases / total metastases is 16.94 / 100, while those treated with other adjuvant is 8.33 / 100.
Human Collagen 'Fingerprints' Produced by Clostridiopeptidase ADigestion and High-Pressure Liquid Chromatography
Recent studies have revealed the existence of at least four structurally distinct types of collagen (see reviews by Gross, 1974; Gallop & Paz, 1975). Type I tropocollagen, consisting oftwo identical al(I) chains and one a2 chain, is the predominant form in bone, dentin, tendon and adult dermis, whereas type II, composed of three al(II) chains, is found in cartilage and intervertebral disc. Type III, made of three al(III) chains, is present in dermis, blood vessels and synovium, and type IV, the basement-membrane collagen, contains three al(IV) chains. It is apparent from the distribution of these collagens that some tissues contain more than one type of collagen (Bradley et al., 1974; Epstein, 1974; Seyer et al., 1974a,b; Trelstad, 1974; Eyre & Muir, 1975b,c). This heterogeneity, together with variations in the post-translational modifications of the collagen molecule and the insolubility of the collagen fibres (Henneman, 1972), complicates the study of the primary structure of tissue collagen. With a view to facilitating the study of human genetic connective-tissue diseases with suspected primary-structure anomalies of collagen (McKusick, 1972), we have developed a technique of analysing the primary structure of collagen by using highpressure liquid-chromatographic separation of the peptides released from collagen by clostridial collagenase. We describe the specific 'fingerprints' obtained by high-pressure liquid chromatography of the peptides released from human type I, II and III collagen by clostridiopeptidase A. We also show that this technique is suitable for the analysis ofminute amounts of collagen.
Stem cells at birth are affected by external factors and aging
Dr. Svetla Bogdanova, a specialist neurologist. He graduated in medicine in 1985 at the Medical University of Pleven, Bulgaria. In 1990 acquired specialty of neurology at the Medical University - Sofia, Bulgaria.
Passed courses and specializations in "Thermal burns" to MHATEM "Pirogov", "General EEG" at the Medical University - Sofia neurophysiology, "Doppler Neurosonology" at the Medical University - Sofia "Health Management" at the Medical University - Plovdiv. She has worked as head of the Regional Coordination Headquarters - Center for Emergency Medical Care, Sofia. He is currently a neurologist at Military Medical Academy and Medical Manager of Tissue stem cell bank "Biohelenika."
Really stem cells gives rise to the human body?
For the last 4-5 years in many international forums symposia and publications advocates topic of stem cells. Detailing their meaning and application. Each organ is composed of cells, such as liver is composed of hepatocytes, neurons of the brain, bone osteocytes, blood leukocytes and erythrocytes from lung pulmotsin etc. All these cells are highly specialized and differentiated function they perform. Stem cells are precisely those that develop in the earliest stages of embryonic development and have assigned a function to be performed. This is what is valuable. They have the original genetic material of an individual, not differentiated, ie the future is ahead of them and can be converted (transformed) into specialized cells of various organs. The most important thing about stem cells is that they are born the youngest cells, unaffected by external factors and aging. This is unique.
Is proven and diseases which are used?
Bone marrow transplantation was first performed in 1968 Bone marrow cells are used to treat patients diagnosed with leukemia, aplastic anemia, lymphoma, Hodgkin's disease, immune disorders, cancer. We know how is hard to find a suitable donor, how long to wait and how costly it. The decision to proceed with private banking (storage) of stem cells, so is the business organization and authorization of Biohelenika - stem cell bank, of which I am medical director. Modern medicine has come to the conclusion that everyone is good to have available their own stem cells.
Since 1988, stem cells from umbilical cord was successfully applied to replace the bone marrow. Stem cell transplants allow treatment of many serious diseases. This type of therapy have proven their undeniable advantage in the treatment of blood cancers - leukemia and lymphoma, is increasing. 107.3 to 100 thousand in 2005
Scientists create teeth with implants grown from stem cells
We want it or not, teeth wear out with age comes a time when you need to replace them with artificial ones. But now there may be an alternative to artificial prostheses - and it is real teeth, "grown" in a lab and created by human cells wreath.
Studies were conducted with mouse stem cells are derived from embryos and specially selected so as to be able to produce growth in other cells to grow out of their teeth. So the combination of murine stem cells and human gingival cells in the laboratory has produced a real tooth - shaped with enamel and roots. The roots were fully alive, suggesting that transplanted into human mouth, most likely belonged to the bone.
The results of this discovery may mean turning point in the treatment of periodontal disease and produce new teeth in people who for some reason have lost their. Of course, the stem cells in the formation of teeth, suitable for implantation in humans must be human rather than mouse and extracting stem cells from human embryos for scientific purposes is not perceived as ethical. Scientists argue that stem cells can be easily extracted from the pulp of human wisdom as to produce the same effect.
Remains of Extinct Giant Camel Discovered in High Arctic
A research team led by the Canadian Museum of Nature has identified the first evidence for an extinct giant camel in Canada's High Arctic. The discovery is based on 30 fossil fragments of a leg bone found on Ellesmere Island, Nunavut and represents the most northerly record for early camels, whose ancestors are known to have originated in North America some 45 million years ago.
The fossils were collected over three summer field seasons (2006, 2008 and 2010) and are about three-and-a-half million years old, dating from the mid-Pliocene Epoch. Other fossil finds at the site suggest this High Arctic camel lived in a boreal-type forest environment, during a global warm phase on the planet.
The research by Dr. Natalia Rybczynski and co-authors including Dr. John Gosse at Dalhousie University, Halifax and Dr. Mike Buckley at the University of Manchester, England is described in the March 5, 2013 edition of the online journal Nature Communications.
"This is an important discovery because it provides the first evidence of camels living in the High Arctic region," explains Rybczynski, a vertebrate paleontologist with the Canadian Museum of Nature, who has led numerous field expeditions in Canada's Arctic. "It extends the previous range of camels in North America northward by about 1,200 km, and suggests that the lineage that gave rise to modern camels may been originally adapted to living in an Arctic forest environment."
The camel bones were collected from a steep slope at the Fyles Leaf Bed site, a sandy deposit near Strathcona Fiord on Ellesmere Island. Fossils of leaves, wood and other plant material have been found at this site, but the camel is the first mammal recovered. A nearby fossil-rich locality at Strathcona Fiord, known as the Beaver Pond site, has previously yielded fossils of other mammals from the same time period, including a badger, deerlet, beaver and three-toed horse.
Determining that the bones were from a camel was a challenge. "The first time I picked up a piece, I thought that it might be wood. It was only back at the field camp that I was able to ascertain it was not only bone, but also from a fossil mammal larger than anything we had seen so far from the deposits," explains Rybczynski, relating the moment that she and her team had discovered something unusual.
Some important physical characteristics suggested the fossil fragments were part of a large tibia, the main lower-leg bone in mammals, and that they belonged to the group of cloven-hoofed animals known as arteriodactyls, which includes cows, pigs and camels. Digital files of each of the 30 bone fragments were produced using a 3D laser scanner, allowing for the pieces to be assembled and aligned. The size of the reconstituted leg bone suggested it was from a very large mammal. At the time in North America, the largest arteriodactyls were camels.
Full confirmation that the bones belonged to a camel came from a new technique called "collagen fingerprinting" pioneered by Dr. Mike Buckley at the University of Manchester in England. Profiles produced by this technique can be used to distinguish between groups of mammals.
Minute amounts of collagen, the dominant protein found in bone, were extracted from the fossils. Using chemical markers for the peptides that make up the collagen, a collagen profile for the fossil bones was developed. This profile was compared with those of 37 modern mammal species, as well as that of a fossil camel found in the Yukon, which is also in the Canadian Museum of Nature's collections.
The collagen profile for the High Arctic camel most closely matched those of modern camels, specifically dromedaries (camels with one hump) as well as the Yukon giant camel, which is thought to be Paracamelus, the ancestor of modern camels. The collagen information, combined with the anatomical data, allowed Rybczynski and her colleagues to conclude that the Ellesmere bones belong to a camel, and is likely the same lineage as Paracamelus.
"We now have a new fossil record to better understand camel evolution, since our research shows that the Paracameluslineage inhabitated northern North America for millions of years, and the simplest explanation for this pattern would be that Paracamelus originated there," explains Rybczynski. "So perhaps some specializations seen in modern camels, such as their wide flat feet, large eyes and humps for fat may be adaptations derived from living in a polar environment."
The scientific paper also reports for the first time an accurate age of both the Fyles Leaf Bed site and the Beaver Pond site -- at least 3.4 million years old. This was determined by Dr. John Gosse at Dalhousie University using a sophisticated technique that involves dating the sands found associated with the bone. The date is significant because it corresponds to a time period when Earth was 2ºC à 3ºC warmer than today, and the Arctic was 14ºC à 22ºC warmer. The bones of the High Arctic camel are housed in the Canadian Museum of Nature's research and collections facility in Gatineau, Quebec on behalf of the Government of Nunavut.
Bee poison stops the spread of HIV
Nanoparticles carrying substance in bee venom can successfully stop the spread of HIV
Chemicals found in bee venom can stop the spread of HIV.
U.S. researchers found that nanoparticles carrying substance in bee venom can successfully stop the spread of HIV, which causes AIDS, said the "Daily Mail".
Toxins from the sting of these insects attack only successful virulent organisms, leaving surrounding cells intact.
The active substance in bee venom, destroying the human immunodeficiency virus, called melitin. It pierced the outer protective shell of the virus and kill it.
The study was led by Dr. Joshua Hood the medicine at Washington University.
He directed the team's efforts in the development of vaginal gel nanoparticles to eliminate the infection still in its infancy.
Until now most familiar to medical drugs only slow the progress of the virus, while the venom he successfully attacked and eradicated.
Even more significantly, in the words of Dr. Hood, HIV can not adapt and counter melitina.
"Our hope is that in places where HIV is widespread, people can use the gel as a precaution to prevent any infection," said study authors.
Pills may help you live to 150 years ...
Scientists develop pill that can help people to live to 150 years, slowing the aging process, reported the British newspaper "Daily Telegraph".
Drugs are synthetic versions of the organic chemical resveratrol, found in red wine, which is believed to slow aging, enhances the activity of the protein SIRT1. The pharmaceutical company GlaxoSmithKline (GSK) drug testing on people suffering from diabetes of the second type and psoriasis.
Professor of Genetics at Harvard University David Sinclair said that aging can not "irreversible catastrophe." "We now investigate whether a benefit for people who are already healthy. Results are promising. We find that aging is irreversible disaster, as previously thought. Certain people may live up to 150 years, but it will not get there without further research" he said.
Professor Sinclair said that the efforts of the activity of SIRT1 protein enhances cell activity, reducing their laziness. Previous experiments on mice, bees and flies that received the substances that enhance the activity of the protein showed that they live longer.
Professor Sinclair allegedly performed experiments which showed that the substances based on resveratrol have a direct impact on health. Some scholars argue that the impact is real and experimental stealth. The results were published in the scientific journal "Science", wrote Thursday.
Despite the controversy, some experiments that promise for diseases such as cancer, cardiovascular disease and heart failure, diabetes of the second type, Alzheimer's, Parkinson's, fatty liver disease, cataracts, osteoporosis, muscle atrophy, sleep disorders and inflammatory diseases such as psoriasis, arthritis and colitis.
In the present study aimed to determine how these substances can help cure diseases associated with aging. But Professor Sinclair believes that in time will also examine the preventive effect. As statins are used today to prevent heart disease and stroke, as these substances can be used to delay many diseases, says the researcher.
Primer caso documentado de curación del sida infantil
Un bebé de dos años que nació con el VIH ha sanado con terapia antirretroviral precoz
Ayer, investigadores de amfAR, (Fundación para la investigación del sida en Estados Unidos) hicieron público en el marco de la 2013 Conference on Retroviruses and Opportunistic Infections, el primer caso documentado de curación de sida en un bebé nacido con VIH. Esta sanación, que fue posible con terapia precoz de antirretrovirales según los médicos, señala la necesidad de investigar más sobre el efecto de estos tratamientos en recién nacidos.
Deborah Persaud, doctora de la Johns Hopkins University de Estados Unidos, describió ayer, tres de marzo de 2013, el primer caso documentado de un bebé curado del sida. Su anuncio fue realizado en la 2013 Conference on Retroviruses and Opportunistic Infections (CROI) de Atlanta (EEUU).
Persaud, investigadora de amfAR (The Foundation for AIDS Research) , detalló el caso de un bebé de dos años de edad de Mississippi diagnosticado con VIH al nacer, y que enseguida fue sometido a terapia antirretroviral.
A los 18 meses, el bebé dejó de tomar los antirretrovirales y su seguimiento médico se interrumpió. Cuando los médicos volvieron a verlo a los 23 meses, a pesar de que había dejado de su terapia durante cinco meses, constataron que el bebé tenía una carga viral indetectable. Una batería de pruebas altamente sensibles posteriores confirmó la ausencia del VIH.
La confirmación de la curación fue posible gracias a una donación que amfAR concedió a la doctora Persaud y a la doctora Katherine Luzuriaga, de la Universidad de Massachusetts, en septiembre de 2012.
La donación permitió que las médicos establecieran un colaboratorio de investigación para explorar y documentar posibles casos pediátricos de curación del VIH. En este colaboratorio participan además los doctores e investigadores Stephen Spector y Richman Doug, de la Universidad de California, San Diego; el Dr. Frank Maldarelli, del Instituto Nacional del Cáncer, y el Dr. Tae-Wook Chun, del Instituto Nacional de Alergias y Enfermedades Infecciosas.
Diversas formas de tratamiento del VIH
"El pediatra del bebé de Mississippi conocía nuestro trabajo y comunicó el caso a nuestro equipo, tan pronto como se enteró," explica Rowena Johnston, vicepresidenta de amfAR. "Gracias a que este colaboratorio ya estaba en marcha, los investigadores pudieron movilizarse inmediatamente y realizar las pruebas necesarias para determinar si realmente se trataba de un caso de curación del SIDA infantil”.
Según Persaud, pruebas exhaustivas han confirmado sin lugar a dudas que la madre y el bebé eran VIH positivo cuando este nació, y que en la actualidad no quedan signos de infección por VIH en el bebé, según los análisis realizados con los medios más sensibles disponibles.
El único caso documentado de cura del VIH hasta la fecha había sido el de Timothy Brown, el llamado "paciente de Berlín." En 2006, mientras era tratado por el VIH, al Sr. Brown le diagnosticaron leucemia.
Su médico trató entonces su leucemia con un trasplante de células madre de una persona nacida con una mutación genética que causa la inmunidad a la infección por VIH. Después del trasplante, el Sr. Brown pudo abandonar el tratamiento para el VIH sin recaídas.
Este nuevo caso apunta a la posibilidad de que diferentes poblaciones de personas con VIH podrían ser curadas de esta enfermedad de diferentes maneras. Mientras que el caso del señor Brown fue el resultado de una serie de complejos y costoso procedimientos de alto riesgo, este nuevo caso parece haber sido el resultado directo de una terapia antirretroviral relativamente barata.
"Teniendo en cuenta que esta sanación parece haberse logrado solo con terapia antirretroviral, es imperativo que aprendamos más acerca del sistema inmunológico de los recién nacidos y en qué se diferencia este del sistema inmunológico de los adultos; así como sobre los factores que han hecho posible que el bebé se haya curado”, explica Johnston.
El caso de Mississippi también pone de relieve la importancia de la identificación del VIH en mujeres embarazadas y de ampliar el acceso a tratamientos para prevenir la transmisión materno-infantil de la enfermedad. Asimismo, revela la necesidad de tratar de inmediato con antirretrovirales a los bebés que nacen seropositivos.
Acerca de amfAR
amfAR, la Fundación para la Investigación del SIDA, es una de las principales organizaciones sin fines de lucro del mundo dedicada al apoyo de la investigación del SIDA, prevención del VIH, educación, tratamiento y su incidencia en las políticas públicas. Desde 1985, amfAR ha invertido más de 366 millones de dólares (unos 280 millones de euros) en sus programas y ha otorgado becas a más de 2.000 equipos de investigación de todo el mundo.